Methods and compositions for treating wounds utilizing chitosan compounds
Inventors
Baker, Shenda • Wiesmann, William P. • Baxter, Ruth
Assignees
Interested in licensing this patent?
MTEC can help explore whether this patent might be available for licensing for your application.
Publication Number
US-9439925-B2
Publication Date
2016-09-13
Expiration Date
Abstract
Described herein are methods of treating wounds, the method comprising administering to a subject an effective amount of a composition comprising a soluble or derivatized chitosan wherein the soluble or derivatized chitosan when administered contacts the wound, thereby treating the wound.
Core Innovation
The invention relates to a method of treating mucositis or ulceration in the gastrointestinal (GI) tract by administering to a subject an effective amount of a composition comprising a soluble or derivatized chitosan. The derivatized chitosan comprises a chitosan of formula (I) having an integer n between 20 and 6000, and each R1 is independently selected from hydrogen, acetyl, and a group of formula (II). The composition is constrained so that at least 25% of R1 substituents are H, at least 1% of R1 substituents are acetyl, and 4-30% of R1 substituents are a group of formula (II).
The derivatized chitosan further includes embodiments where R2 is hydrogen or amino, including protected amino, and R3 contains amino/guanidino functionalities, including guanidino/arginine/lysine/histidine side chains, substituted C1-C6 alkyls, and amino-acid side chain embodiments. The disclosure also describes additional properties including molecular weight ranges, aqueous solubility pH windows, degree of functionalization, degree of deacetylation, polydispersity index, and impurity-free constraints. These compositions are described for treating mucositis or ulceration and related GI tract conditions.
The document further states use in reducing inflammation and improving healing outcomes, including reduced healing time and increased healing rate. It also describes wound dressing concepts incorporating the soluble or derivatized chitosan, including biocompatible pad structures and negative-pressure wound dressing features. Beyond GI mucositis and ulceration, the disclosure references treatment of inflammation not associated with bacterial infection and wound healing in acute or chronic contexts, including surgical, burn, and ulcer wound types.
Claims Coverage
The provided claim coverage centers on 1 independent claim directed to treating mucositis or ulceration in the GI tract by administering an effective amount of a soluble or derivatized chitosan composition. The independent inventive features are the defined chitosan formula (I) with n between 20 and 6000 and the constrained R1 substitution pattern; dependent refinements add anatomical location, healing and inflammation outcomes, molecular weight, and subject context.
Treating gi mucositis or ulceration with soluble or derivatized chitosan
A method of treating mucositis or ulceration in the gastrointestinal (GI) tract by administering to a subject an effective amount of a composition comprising a soluble or derivatized chitosan.
Chitosan formula (I) with constrained n value
The derivatized chitosan comprises a chitosan of formula (I) wherein n is an integer between 20 and 6000.
R1 substitution pattern with hydrogen, acetyl, and a group of formula (II)
Each R1 is independently selected from hydrogen, acetyl, and a group of formula (II), with at least 25% of R1 substituents being H, at least 1% being acetyl, and 4-30% being a group of formula (II).
Molecular weight constraint for functionalized chitosan
The functionalized chitosan has a molecular weight between 5,000 and 1,000,000 Da.
Treatment in subjects exposed to radiation or chemotherapy
The subject has been exposed to radiation or chemotherapy.
Specified gi or oral tract locations
The mucositis or ulceration occurs in the mouth, tongue, throat, esophagus, stomach, large intestine, small intestine, colon, or rectum.
Healing and inflammation outcomes
The composition reduces healing time or increases healing rate, and reduces inflammation when mucositis or ulceration is associated with inflammation.
The claims are anchored by administration of a soluble or derivatized chitosan for GI mucositis or ulceration, with formula (I), n between 20 and 6000, and the specified R1 distribution as the core inventive limitation. The remaining claim features refine location, outcomes, molecular weight, and subject context.
Stated Advantages
Reduces healing time or increases healing rate of mucositis or ulceration.
Reduces inflammation when inflammation is associated with mucositis or ulceration.
Enhanced wound healing and reduced inflammation.
Documented Applications
Treating mucositis or ulceration in the gastrointestinal (GI) tract.
Treating mucositis or ulceration in specified regions including the mouth, tongue, throat, esophagus, stomach, large intestine, small intestine, colon, or rectum.
Treating wounds and chemical/biological/radiological injury.
Prophylactic administration for chemical warfare agents.
Wound dressing incorporating the soluble or derivatized chitosan, including negative-pressure wound dressing features.
Treating inflammation not associated with bacterial infection.
Wound healing in acute or chronic contexts, including surgical, burn, and ulcer wound types.
Treating GI conditions via pH-dependent solubility.
Interested in licensing this patent?